Warfarin is the most prescribed oral anticoagulant worldwide. Because of the complexity of warfarin therapy, we attempted to dissect genetic from bioenvironmental factors influencing warfarin dose responses in individuals of a genetic isolate of Hispanic ancestry. A total of 191 patients with standard values of international normalized ratio were recruited. Three groups with a significantly different warfarin dose response were identified, that is, sensitive (2.28 ± 0.50 mg/d), intermediate (4.2 ± 0.76 mg/d), and resistant (7.40 ± 1.54 mg/d; Tukey test, P < .001). Age had a significant inverse correlation with warfarin dose (P < .001; effective dose diminished 0.56 mg/d/decade). Required doses were higher for individuals with CYP2C9 variants containing the allele *1 compared to those individuals with variants composed of other alleles (P = .006). Similarly, individuals with VKORC1-1639GG and VKORC1-1639GA genotypes also required higher doses compared to the AA genotype (P < .001). Evaluation of potential gene-gene interactions between CYP2C9 and VKORC1 polymorphisms showed significant differences in dosing for CYP2C9 genotypes within the VKORC1-1639G/A subgroup (P = .013). A stepwise multivariate linear regression analysis showed that 38.2% of the warfarin dose response variance was accounted for by a model involving age (20.9%), VKORC1-1639G/A (11.3%), and CYP2C9*1, *2, and *3 variants (7.1%). These results corroborate previous findings on warfarin pharmacogenetics and define a contrastable gene-bioenvironment interaction model suited to be used in Hispanic populations.
Hirsh J., Dalen J., Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001 ;119:8S-21S.
2.
Fanikos J., Grasso-Correnti N., Shah R., Kucher N., Goldhaber SZMajor bleeding complications in a specialized anticoagulation service. Am J Cardiol. 2005;96: 595-598.
3.
Hatch E., Wynne H., Avery P., Wadelius M., Kamali F.Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients. J Thromb Haemost. 2008;6: 1038-1040.
4.
Wynne HA, Kamali F., Edwards C., Long A., Kelly P.Effect of ageing upon warfarin dose requirements: a longitudinal study. Age Ageing. 1996;25:429-431.
5.
Daly AK, King BPPharmacogenetics of oral anticoagulants. Pharmacogenetics . 2003;13:247-252.
6.
Hirsh J., Bates SMClinical trials that have influenced the treatment of venous thromboembolism: a historical perspective. Ann Intern Med. 2001;134:409-417.
7.
Oldenburg J. , Watzka M., Rost S., Muller CRVKORC1: molecular target of coumarins. J Thromb Haemost. 2007;5(suppl 1):1-6.
8.
Rost S., Fregin A., Hunerberg M., Bevans CG, Muller CR, Oldenburg J.Site-directed mutagenesis of coumarintypeanticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb Haemost. 2005;94:780-786.
9.
Rost S., Fregin A., Ivaskevicius V., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427: 537-541.
10.
Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-2293.
11.
Kimura R., Miyashita K., Kokubo Y., et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res. 2007;120: 181-186.
12.
Wadelius M. , Pirmohamed M.Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007;7:99-111.
13.
Rettie AE, Tai G.The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv. 2006;6: 223-227.
14.
Haining RL, Jones JP, Henne KR, et al. Enzymatic determinants of the substrate specificity of CYP2C9: role of B’-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry. 1999;38: 3285-3292.
15.
Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 1997;7:361-367.
16.
Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AEAllelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996;333:447-458.
17.
Wu AH, Wang P., Smith A., et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics. 2008;9:169-178.
18.
Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity . Hum Mol Genet. 2005;14:1745-1751.
19.
Crawford DC, Ritchie MD, Rieder MJIdentifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. Pharmacogenomics . 2007;8:487-496.
20.
Geisen C., Watzka M., Sittinger K., et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005;94:773-779.
21.
Arcos-Burgos M., Castellanos FX, Lopera F., et al. Attentiondeficit/hyperactivity disorder (ADHD): feasibility of linkage analysis in a genetic isolate using extended and multigenerational pedigrees. Clin Genet. 2002;61:335-343.
22.
Arcos-Burgos M., Muenke M.Genetics of population isolates. Clin Genet. 2002;61:233-247.
23.
Arcos-Burgos M., Castellanos FX, Pineda D., et al. Attention-deficit/hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11 . Am J Hum Genet. 2004;75:998-1014.
24.
Bravo ML, Valenzuela CY, Arcos-Burgos OMPolymorphisms and phyletic relationships of the Paisa community from Antioquia (Colombia). Gene Geogr. 1996;10: 11-17.
25.
Moridani M. , Fu L., Selby R., et al. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. Clin Biochem. 2006;39: 606-612.
26.
Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106: 2329-2333.
27.
Montes R., Ruiz de Gaona E., Martinez-Gonzalez MA, Alberca I., Hermida J.The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol. 2006;133:183-187.
Gage BF, Eby C., Milligan PE, Banet GA, Duncan JR, McLeod HLUse of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91:87-94.
30.
Voora D., McLeod HL, Eby C., Gage BFThe pharmacogenetics of coumarin therapy. Pharmacogenomics . 2005;6: 503-513.
31.
Kamali F., Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 2004;75:204-212.
32.
Sconce E., Avery P., Wynne H., Kamali F.Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood . 2007;109:2419-2423.
33.
Herman D., Peternel P., Stegnar M., Breskvar K., Dolzan V.The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement . Thromb Haemost. 2006;95:782-787.
34.
Obayashi K. , Nakamura K., Kawana J., et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther. 2006;80:169-178.
35.
Takahashi H. , Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006;16:101-110.
36.
Pelz HJ, Rost S., Hunerberg M., et al. The genetic basis of resistance to anticoagulants in rodents . Genetics. 2005;170: 1839-1847.
37.
Loebstein R. , Dvoskin I., Halkin H., et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007;109:2477-2480.
